Cytodyn Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
CytoDyn Inc. is a development-stage biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. In addition, the Company formed a wholly owned subsidiary, CytoDyn Veterinary Medicine LLC (CVM), which will explore the possible application of its existing monoclonal antibody technology to the treatment of Feline Immunodeficiency Virus, a retroviral infection in cats (FIV). CytoDyn and Cytolin are the registered trademarks of the Company. In October 2012, the Company acquired PRO 140, an experimental humanized monoclonal antibody (mAb) targeting the CCR5 receptor for the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. PRO 140 is a humanized monoclonal antibody designed to block HIV from entering a cell. Cytolin is the Company's lead product. It targets a normal cell molecule called CD11a.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
